



Date of submission: February 13, 2026

To, The Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code –539551(EQ), 975516 & 976418	To, The Secretary Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051 Scrip Code- NH
--	--

Dear Sir/Madam,

Sub: Press Release for the quarter ended December 31, 2025 and Call invite

With reference to the subject, please find enclosed the Press Release for the quarter ended December 31, 2025.

Further to our letter dated February 11, 2026, please find attached the call invite to discuss the Company's performance on **Tuesday, February 17, 2026 at 03:00 p.m. IST.**

Kindly take the above information on record.

Thanking you

Yours faithfully
For **Narayana Hrudayalaya Limited**

Sridhar S.
Group Company Secretary, Legal & Compliance Officer

Encl.: as above

PRESS RELEASE – Q3 FY26 Results

Q3 FY26 Consolidated operating revenue at ₹ 21,512 Mn (YoY growth of 61.2%) with Adj. EBITDA of ₹ 4,662 Mn (YoY growth of 19.9%)

Bengaluru, India, February 13th, 2026 – Narayana Hrudayalaya Limited, a leading healthcare service provider, announced its financial results for the third quarter (Q3 FY26) ended December 31st, 2025.

₹ Mn	Q3FY26	Q3FY25	YoY %
India Revenue ⁽¹⁾	11,796	10,552	11.8%
Cayman Revenue ⁽²⁾	4,991	2,935	70.0%
UK Revenue ⁽²⁾	4,902	-	-
Consol Revenue ⁽³⁾	21,512	13,346	61.2%
Consol Adj. EBITDA ⁽⁴⁾	4,662	3,257	43.1%
Adj. EBITDA margin	21.7%	24.4%	
Adj. PAT ⁽⁴⁾	2,548	1,936	31.6%
Adj. PAT %	11.8%	14.5%	
Profitability before Adjustment of One-time costs			
Consol EBITDA	3,904	3,257	19.9%
EBITDA margin	18.2%	24.4%	
PAT	1,281	1,936	-33.9%
PAT %	6.0%	14.5%	

Notes

(1) India and Consolidated numbers are adjusted with NVDSHPL.

(2) Cayman & UK nos. are converted from USD to INR at 87.35 for Q3FY26, and 83.89 for Q3FY25. UK numbers are converted from GBP to USD at 1.33 for Q3 FY26. The numbers may slightly vary on conversion due to different exchange rates applicable at different reporting periods. UK revenue for Q3 FY26 is considered from date of acquisition i.e., 6th November 2025.

(3) Consol revenue numbers are adjusted for Inter-company eliminations.

(4) Q3 FY26 - EBITDA is adjusted with one time acquisition cost of ₹ 757 Mn and PAT is further adjusted with one time impact due to new labor code of ₹ 509 Mn.

Financial Highlights for the Quarter (Q3 FY26) - Prepared in accordance with Ind AS ('Indian Accounting Standards')

- Consolidated total operating revenue was ₹ 21,512 Mn for Q3 FY26 as compared to ₹ 13,346 Mn in the corresponding period of the previous year, reflecting a change of +61.2 % YoY and +30.9% QoQ.
- Consolidated Adj. EBITDA stood at ₹ 4,662 Mn, reflecting a margin of 21.7% as against ₹ 3,257 Mn in Q3 FY25, translating into a change of +43.1% YoY and +9.3% QoQ.
- Consolidated Adj. PAT stood at ₹ 2,548 Mn, reflecting a margin of 11.8% as compared to ₹ 1,936 Mn in Q3 FY25, translating into a change of +31.6% YoY and -1.4% QoQ.
- India operating revenue was ₹ 11,796 Mn for Q3 FY26 as compared to ₹ 10,552 Mn in the corresponding period of the previous year, reflecting a change of +11.8% YoY and -4.5% QoQ.
- Cayman operating revenue was ₹ 4,991 Mn for Q3 FY26 as compared to ₹ 2,935 Mn in the corresponding period of the previous year, reflecting a change of +70.0% YoY and +15.6% QoQ.
- UK operating revenue was ₹ 4,902 Mn for Q3 FY26 starting from 6th November 2025.

As on December 31st, 2025, the Total Borrowings less Cash & Bank Balance and Investments were INR 22,321 Mn, representing a net debt to equity ratio of 0.53 (Out of which, debt worth US\$ 119 Mn and GBP £150 Mn are foreign currency denominated).

Other Highlights during the Quarter

- Narayana Institute of Cardiac Sciences, Bangalore** has performed:
 - 244 robotic cardiac surgeries (35% increase QoQ).
 - 48 TAVIs (50% increase YoY).
- Narayana Super-specialty Hospital, Howrah** has performed Complex Pediatric Interventions – 3 Transcatheter Fontan procedure, 2 Sinus venosus ASD Stenting procedure and 2 Coronary Cameral Fistula Device Closure.
- Narayana Multi-specialty Hospital, Ahmedabad** has successfully completed its first ever heart transplant in December'25.

Management Comment

Commenting on the performance, **Dr. Emmanuel Rupert, Managing Director and Group CEO, Narayana Hrudayalaya Limited**, said "After a strong second quarter, we are pleased to report the highest-ever revenue at the Group level in the third quarter. During the quarter, the Company completed the acquisition of Practice Plus Group Hospitals in UK, with effect from 6th November 2025. The financial statements of this subsidiary have been consolidated from this quarter onwards. The acquisition aligns with the Company's strategy to expand its international footprint and establish its presence in the UK market. India continues to perform well on account of steady footfall and higher realizations due to payor mix optimization and improved usage of technology across both clinical and non-clinical platforms. Our hospital business in Cayman continues to deliver robust performance, with the Insurance business showing steady growth, resulting in record revenues for the region. We are confident that the synergies between the hospital and insurance businesses will deliver steady growth going forward in the Cayman region. The domestic Integrated Care business continues to be on a strong growth path, and after a steady start, our domestic Insurance business has shown strong momentum this quarter, which we expect to build on going forward. We thank the investor community for their faith in us and remain confident of delivering on expectations for the year."

About Narayana Hrudayalaya Limited

Founded in 2000 by Dr. Devi Prasad Shetty and headquartered in Bengaluru, Narayana Hrudayalaya Limited is one of the leading healthcare service providers, operating a chain of multispecialty, tertiary, and primary healthcare facilities. The Company has a network of 55 Healthcare facilities spread across India along with overseas presence at Cayman Islands and United Kingdom, with over 5,900 operational beds and a capacity of over 6,200 beds.

For further details, please contact:

Nishant Singh
nishant.singh@narayanahealth.org
+91.8369353821

Vivek Agarwal
vivek.agarwal@narayanahealth.org
+91.9510756827

investorrelations@narayanahealth.org

Important Disclaimer

No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects, and future developments in its industry and its competitive and regulatory environment.

Actual results may differ materially from these forward-looking statements due to a number of factors, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions in India.

This communication is for general information purpose only, without regard to specific objectives, financial situations and needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any shares in the Company and neither any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and/or disseminated in any manner.

Q3 FY26 Result Conference Call

At 03:00 PM, IST on February 17th, 2026

Following the announcement of the third quarter (Q3 FY26) ended December 31st, 2025, results on February 13th, 2026, the management of Narayana Hrudayalaya Limited will host a conference call to discuss the Company's performance on February 17th, 2026, at 03:00 pm IST.

Date:	Tuesday, February 17 th , 2026										
Time:	03:00 pm IST										
Zoom Dial-in Details:											
Details of Conference call	<p style="text-align: center;">Click here to Join the Conference Call</p> <p>Meeting ID: 835 9591 0387</p> <p>Passcode: 704430</p> <p><u>Conference dial-in by your location</u></p> <table border="1"><tr><td>US</td><td>▪ +1 646 931 3860</td></tr><tr><td>Singapore</td><td>▪ +65 3129 4892</td></tr><tr><td>Mexico</td><td>▪ +52 558 659 6002</td></tr><tr><td>Russia</td><td>▪ +7 499 951 6380</td></tr><tr><td>Japan</td><td>▪ +81 3 4579 0545</td></tr></table>	US	▪ +1 646 931 3860	Singapore	▪ +65 3129 4892	Mexico	▪ +52 558 659 6002	Russia	▪ +7 499 951 6380	Japan	▪ +81 3 4579 0545
	US	▪ +1 646 931 3860									
Singapore	▪ +65 3129 4892										
Mexico	▪ +52 558 659 6002										
Russia	▪ +7 499 951 6380										
Japan	▪ +81 3 4579 0545										
Transcript	The transcript will be uploaded on our website www.narayanahealth.org										